Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7 Suppl
|
| pubmed:dateCreated |
1995-11-22
|
| pubmed:abstractText |
The efficacy and safety of a 10-day course of ceftibuten oral suspension (9 mg/kg once daily) were compared with those of penicillin V (25 mg/kg/day in 3 divided doses) in children 3 to 18 years old treated for symptomatic pharyngitis and scarlet fever caused by group A beta-hemolytic streptococci (Streptococcus pyogenes). The study was prospective, randomized, multicenter and investigator-blinded; patients were randomized in a 2:1 ratio (ceftibuten:penicillin V). Overall clinical success (cure/improvement) at the primary end point of treatment (5 to 7 days posttherapy) was achieved in 97% (285 of 294) of ceftibuten-treated patients vs. 89% (117 of 132) of penicillin V-treated patients (P < 0.01). Elimination of infecting streptococci 5 to 7 days posttherapy was achieved in 91% (267 of 294) of ceftibuten-treated patients vs 80% (105 of 132) of penicillin V-treated patients (P < 0.01). A significant rise in anti-streptolysin O or anti-DNase B was observed in approximately 30% of patients in both treatment groups. No patient developed rheumatic fever or nephritis. Treatment-related adverse events were similar between the two groups; mild vomiting (2%) was most frequently reported. These data suggest that once daily ceftibuten is as safe as and more effective than three times daily penicillin V for the treatment of group A beta-hemolytic streptococcal pharyngitis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cephalosporins,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillin V,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillins,
http://linkedlifedata.com/resource/pubmed/chemical/Suspensions,
http://linkedlifedata.com/resource/pubmed/chemical/ceftibuten
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0891-3668
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S102-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7567309-Adolescent,
pubmed-meshheading:7567309-Cephalosporins,
pubmed-meshheading:7567309-Child,
pubmed-meshheading:7567309-Child, Preschool,
pubmed-meshheading:7567309-Confidence Intervals,
pubmed-meshheading:7567309-DNA, Bacterial,
pubmed-meshheading:7567309-Double-Blind Method,
pubmed-meshheading:7567309-Female,
pubmed-meshheading:7567309-Humans,
pubmed-meshheading:7567309-Male,
pubmed-meshheading:7567309-Penicillin V,
pubmed-meshheading:7567309-Penicillins,
pubmed-meshheading:7567309-Pharyngitis,
pubmed-meshheading:7567309-Prospective Studies,
pubmed-meshheading:7567309-Scarlet Fever,
pubmed-meshheading:7567309-Streptococcal Infections,
pubmed-meshheading:7567309-Streptococcus pyogenes,
pubmed-meshheading:7567309-Suspensions,
pubmed-meshheading:7567309-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group.
|
| pubmed:affiliation |
University of Rochester Medical Center, NY 14642, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|